[Congressional Bills 110th Congress]
[From the U.S. Government Publishing Office]
[H.R. 741 Introduced in House (IH)]







110th CONGRESS
  1st Session
                                H. R. 741

    To provide for the expansion of Federal efforts concerning the 
 prevention, education, treatment, and research activities related to 
 Lyme and other tick-borne diseases, including the establishment of a 
                Tick-Borne Diseases Advisory Committee.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 31, 2007

   Mr. Smith of New Jersey (for himself, Mr. Stupak, Mr. Holden, Mr. 
Gilchrest, Mr. Shays, Mrs. Lowey, Ms. DeLauro, Ms. Bean, Mr. Langevin, 
   Mr. Baird, Mr. Kirk, Mr. Ackerman, Mr. Grijalva, and Mr. McHugh) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
    To provide for the expansion of Federal efforts concerning the 
 prevention, education, treatment, and research activities related to 
 Lyme and other tick-borne diseases, including the establishment of a 
                Tick-Borne Diseases Advisory Committee.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Lyme and Tick-Borne Disease 
Prevention, Education, and Research Act of 2007''.

SEC. 2. FINDINGS.

    Congress makes the following findings:
            (1) Lyme disease is a common but frequently misunderstood 
        illness that, if not caught early and treated properly, can 
        cause serious health problems.
            (2) Lyme disease is a bacterial infection that is 
        transmitted by a tick bite. Early signs of infection may 
        include a rash and flu-like symptoms such as fever, muscle 
        aches, headaches, and fatigue.
            (3) Although Lyme disease can be treated with antibiotics 
        if caught early, the disease often goes undetected because it 
        mimics other illnesses or may be misdiagnosed. Untreated, Lyme 
        disease can lead to severe heart, neurological, eye, and joint 
        problems because the bacteria can affect many different organs 
        and organ systems.
            (4) If an individual with Lyme disease does not receive 
        treatment, such individual can develop severe heart, 
        neurological, eye, and joint problems.
            (5) Although Lyme disease accounts for 90 percent of all 
        vector-borne infections in the United States, the ticks that 
        spread Lyme disease also spread other diseases, such as 
        ehrlichiosis, babesiosis, and other strains of Borrelia. All of 
        these diseases in 1 patient makes diagnosis and treatment more 
        difficult.
            (6) Studies indicate that the actual number of tick-borne 
        disease cases are approximately 10 times the amount reported.
            (7) Persistence of symptomatology in many patients without 
        reliable testing makes treatment of patients more difficult.

SEC. 3. ESTABLISHMENT OF A TICK-BORNE DISEASES ADVISORY COMMITTEE.

    (a) Establishment.--Not later than 180 days after the date of the 
enactment of this Act, the Secretary of Health and Human Services 
(referred to in this Act as the ``Secretary'') shall establish within 
the Office of the Secretary an advisory committee to be known as the 
Tick-Borne Diseases Advisory Committee (referred to in this section as 
the ``Committee'').
    (b) Duties.--The Committee shall advise the Secretary and the 
Assistant Secretary for Health regarding the manner in which such 
officials can--
            (1) ensure interagency coordination and communication and 
        minimize overlap regarding efforts to address tick-borne 
        diseases;
            (2) identify opportunities to coordinate efforts with other 
        Federal agencies and private organizations addressing such 
        diseases;
            (3) ensure interagency coordination and communication with 
        constituency groups;
            (4) ensure that a broad spectrum of scientific viewpoints 
        are represented in public health policy decisions and that 
        information disseminated to the public and physicians is 
        balanced; and
            (5) advise relevant Federal agencies on priorities related 
        to the Lyme and tick-borne diseases.
    (c) Membership.--
            (1) Appointed members.--
                    (A) In general.--From among individuals who are not 
                officers or employees of the Federal Government, the 
                Secretary shall appoint to the Committee, as voting 
                members, an equal number of individuals from each of 
                the groups described in clauses (i) through (v) of 
                subparagraph (B).
                    (B) Groups.--The groups described in this 
                subparagraph include the following:
                            (i) Scientific community members 
                        representing the broad spectrum of viewpoints 
                        held within the scientific community related to 
                        Lyme and other tick-borne diseases.
                            (ii) Representatives of tick-borne disease 
                        voluntary organizations.
                            (iii) Health care providers, including at 
                        least 1 full-time practicing physician, with 
                        relevant experience providing care for 
                        individuals with a broad range of acute and 
                        chronic tick-borne diseases.
                            (iv) Patient representatives who are 
                        individuals who have been diagnosed with a 
                        tick-borne disease or who have had an immediate 
                        family member diagnosed with such a disease.
                            (v) Representatives of State and local 
                        health departments and national organizations 
                        that represent State and local health 
                        professionals.
                    (C) Diversity.--In appointing members under this 
                paragraph, the Secretary shall ensure that such 
                members, as a group, represent a diversity of 
                scientific perspectives relevant to the duties of the 
                Committee.
            (2) Ex officio members.--The Secretary shall designate, as 
        nonvoting, ex officio members of the Committee, representatives 
        overseeing tick-borne disease activities from each of the 
        following Federal agencies:
                    (A) The Centers for Disease Control and Prevention.
                    (B) The National Institutes of Health.
                    (C) The Agency for Healthcare Research and Quality.
                    (D) The Food and Drug Administration.
                    (E) The Office of the Assistant Secretary for 
                Health.
                    (F) Such additional Federal agencies as the 
                Secretary determines to be appropriate.
            (3) Co-chairpersons.--The Secretary shall designate the 
        Assistant Secretary of Health as the co-chairperson of the 
        Committee. The appointed members of the Committee shall also 
        elect a public co-chairperson. The public co-chairperson shall 
        serve a 2-year term.
            (4) Term of appointment.--The term of service for each 
        member of the Committee appointed under paragraph (1) shall be 
        4 years.
            (5) Vacancy.--A vacancy in the membership of the Committee 
        shall be filled in the same manner as the original appointment. 
        Any member appointed to fill a vacancy for an unexpired term 
        shall be appointed for the remainder of that term. Members may 
        serve after the expiration of their terms until their 
        successors have taken office.
    (d) Meetings.--The Committee shall hold public meetings, except as 
otherwise determined by the Secretary, after providing notice to the 
public of such meetings, and shall meet at least twice a year with 
additional meetings subject to the call of the co-chairpersons. Agenda 
items with respect to such meetings may be added at the request of the 
members of the Committee, including the co-chairpersons. Meetings shall 
be conducted, and records of the proceedings shall be maintained, as 
required by applicable law and by regulations of the Secretary.
    (e) Authorization of Appropriations.--For the purpose of carrying 
out this section, there is authorized to be appropriated $250,000 for 
each of the fiscal years 2008 through 2011. Amounts appropriated under 
the preceding sentence shall be used for the expenses and per diem 
costs incurred by the Committee under this section in accordance with 
the Federal Advisory Committee Act, except that no voting member of the 
Committee shall be a permanent salaried employee.

SEC. 4. FEDERAL ACTIVITIES RELATED TO THE DIAGNOSIS, SURVEILLANCE, 
              PREVENTION, AND RESEARCH OF LYME AND OTHER TICK-BORNE 
              DISEASES.

    (a) In General.--The Secretary, acting as appropriate through the 
Director of the Centers for Disease Control and Prevention, the 
Director of the National Institutes of Health, the Commissioner of Food 
and Drugs, and the Director of the Agency for Healthcare Research and 
Quality, as well as additional Federal agencies as the Secretary 
determines to be appropriate, and in consultation with the Tick-Borne 
Diseases Advisory Committee, shall provide for the coordination of all 
Federal programs and activities related to Lyme and other tick-borne 
diseases, including the activities described in paragraphs (1) through 
(4) of subsection (b).
    (b) Activities.--The activities described in this subsection are 
the following:
            (1) Development of diagnostic tests.--Such activities 
        include--
                    (A) the development of sensitive and more accurate 
                diagnostic tools and tests, including a direct 
                detection test for Lyme disease capable of 
                distinguishing active infection from past infection;
                    (B) improving the efficient utilization of 
                diagnostic testing currently available to account for 
                the multiple clinical manifestations of both acute and 
                chronic Lyme disease; and
                    (C) providing for the timely evaluation of 
                promising emerging diagnostic methods.
            (2) Surveillance and reporting.--Such activities include 
        surveillance and reporting of Lyme and other tick-borne 
        diseases--
                    (A) to accurately determine the prevalence of Lyme 
                and other tick-borne disease;
                    (B) to evaluate the feasibility of developing a 
                reporting system for the collection of data on 
                physician-diagnosed cases of Lyme disease that do not 
                meet the surveillance criteria of the Centers for 
                Disease Control and Prevention in order to more 
                accurately gauge disease incidence; and
                    (C) to evaluate the feasibility of creating a 
                national uniform reporting system including required 
                reporting by laboratories in each State.
            (3) Prevention.--Such activities include--
                    (A) the provision and promotion of access to a 
                comprehensive, up-to-date clearinghouse of peer-
                reviewed information on Lyme and other tick-borne 
                disease;
                    (B) increased public education related to Lyme and 
                other tick-borne diseases through the expansion of the 
                Community Based Education Programs of the Centers for 
                Disease Control and Prevention to include expansion of 
                information access points to the public;
                    (C) the creation of a physician education program 
                that includes the full spectrum of scientific research 
                related to Lyme and other tick-borne diseases; and
                    (D) the sponsoring of scientific conferences on 
                Lyme and other tick-borne diseases, including reporting 
                and consideration of the full spectrum of clinically-
                based knowledge, with the first of such conferences to 
                be held not later than 24 months after the date of 
                enactment of this Act.
            (4) Clinical outcomes research.--Such activities include--
                    (A) the establishment of epidemiological research 
                objectives to determine the long term course of illness 
                for Lyme disease; and
                    (B) determination of the effectiveness of different 
                treatment modalities by establishing treatment outcome 
                objectives.
    (c) Authorization of Appropriations.--For the purposes of carrying 
out this section, and for the purposes of providing for additional 
research, prevention, and educational activities for Lyme and other 
tick-borne diseases, there is authorized to be appropriated $20,000,000 
for each of the fiscal years 2008 through 2012. Such authorization is 
in addition to any other authorization of appropriations available for 
such purpose.

SEC. 5. REPORTS ON LYME AND OTHER TICK-BORNE DISEASES.

    (a) In General.--Not later than 18 months after the date of 
enactment of this Act, and annually thereafter, the Secretary shall 
submit to Congress a report on the activities carried out under this 
Act.
    (b) Content.--Reports under subsection (a) shall contain--
            (1) significant activities or developments related to the 
        surveillance, diagnosis, treatment, education, or prevention of 
        Lyme or other tick-borne diseases, including suggestions for 
        further research and education;
            (2) a scientifically qualified assessment of Lyme and other 
        tick-borne diseases, including both acute and chronic 
        instances, related to the broad spectrum of empirical evidence 
        of treating physicians, as well as published peer reviewed 
        data, that shall include recommendations for addressing 
        research gaps in diagnosis and treatment of Lyme and other 
        tick-borne diseases and an evaluation of treatment guidelines 
        and their utilization;
            (3) progress in the development of accurate diagnostic 
        tools that are more useful in the clinical setting for both 
        acute and chronic disease; and
            (4) the promotion of public awareness and physician 
        education initiatives to improve the knowledge of health care 
        providers and the public regarding clinical and surveillance 
        practices for Lyme disease and other tick-borne diseases.
                                 <all>